Prime Medicine, Inc. (PRME) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
PRME currently has 177M outstanding shares. with moderate dilution risk from 56.5M authorized shares representing 31.9% potential dilution. The company has significantly diluted shareholders by 47.93% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 177.1M shares outstanding |
180M | 56M |
| Aug 07, 2025 |
10-Q filing | 129.2M shares outstanding |
130M | 56M |
| May 08, 2025 |
10-Q filing | 130.9M shares outstanding |
130M | 56M |
| Feb 28, 2025 |
10-K filing | 118.6M shares outstanding |
120M | 56M |
| Dec 13, 2024 |
S-3 filing: The filing is an S-3 form for a shelf registration statement, allowing the selling stockholder to offer and sell shares of the company's common stock. |
120M | 56M |
| Nov 12, 2024 |
10-Q filing | 119.8M shares outstanding |
120M | 56M |
| Sep 30, 2024 |
8-K filing: Prime Medicine, Inc. entered into a Securities Purchase Agreement with Juno Therapeutics, Inc., a wholly-owned subsidiary of Bristol-Myers Squibb Company, to sell and issue 11,006,163 shares of its common stock for $55.0 million, with the closing expected on September 30, 2024. ($55.0M proceeds) |
120M | 56M |
| Aug 08, 2024 |
10-Q filing | 119.2M shares outstanding |
120M | 56M |
| May 10, 2024 |
10-Q filing | 120.0M shares outstanding |
120M | 56M |
| Mar 01, 2024 |
10-K filing | 119.9M shares outstanding |
120M | 56M |
| Nov 03, 2023 |
10-Q filing | 91.8M shares outstanding |
92M | 56M |
| Nov 03, 2023 |
S-3 filing: This S-3 filing relates to an at-the-market offering of common stock with an aggregate offering price of up to $300,000,000. |
97M | 56M |
| Aug 07, 2023 |
10-Q filing | 90.5M shares outstanding |
90M | 10M |
| May 11, 2023 |
10-Q filing | 89.1M shares outstanding |
89M | 10M |
| Mar 09, 2023 |
10-K filing | 97.2M shares outstanding |
97M | 10M |
| Nov 14, 2022 |
10-Q filing | 97.2M shares outstanding |
97M | 10M |
| Oct 17, 2022 |
S-1/A filing: This S-1/A filing registers an offering of 8,900,000 shares of common stock. The company estimates net proceeds of $136.2 million from the sale of these shares, assuming an initial public offering price of $17.00 per share. The underwriters also have an option to purchase up to 1,335,000 additional shares. |
94M | 10M |
| Oct 13, 2022 |
S-1/A filing: This S-1/A filing registers an offering of common stock, with 8,900,000 shares offered by the company and an additional 1,335,000 shares available through the underwriters' option to purchase. The company intends to use the net proceeds for research and development, clinical studies, manufacturing processes, and general corporate purposes. |
85M | 10M |
| Sep 23, 2022 |
S-1 filing: This is an S-1 filing for an IPO of common stock. The number of shares outstanding after the offering is based on 265,603,788 shares as of June 30, 2022, after giving effect to the conversion of preferred stock. |
270M | 0 |